Organs-on-Chips: How Microsystems Technology Can Transform the Drug Development Process.
The drug development pipeline, once one of the most successful and lucrative commercial sectors in the United States, is now strained by a combination of factors: increased development costs, lengthy time lines, and the poor predictive power of preclinical studies, among others. These factors, in combination with the need to respond to newly evolving demands?including the trend toward personalized or precision medicine, rising rates for many chronic diseases, and continued threats from emerging infectious diseases?are placing extraordinary pressure on an already strained development process.